Robert Ring

Robert Ring

Company: Kaerus Bioscience

Job title: Chief Executive Officer

Seminars:

Panel Discussion – Pros and Cons of NDDs and Genetic Epilepsies Treatment Modalities: Gene Therapy, ASOs & Small Molecule Approaches 3:30 pm

In a landscape where potential therapeutic modalities for rare CNS and neurodevelopmental disorders are fast evolving, where should we really be focusing our attention? Exploring the successes and caveats from traditional small molecule therapies to emerging ASO and gene therapy treatments.Read more

day: Day Two

Exploring BK Channelopathies in Fragile X and Other Genetic Syndromes Impacting Neurodevelopment to Illuminate New Frontiers for Functional Biomarkers 2:15 pm

Laying out the rationale for targeting BK channels in therapeutic development for Fragile X and related genetic syndromes of neurodevelopment Introducing the use of electroretinography (ERG) as a quantitative biomarker for advancing BK channel therapeuticsRead more

day: Day Two

Unravelling the Latest Research in Disease Pathology to Explore Future Considerations in Drug Development 11:30 am - 2:30 pm

With both Rett and Fragile X Syndrome having experienced recent clinical failures, there remains a need for greater disease understanding. Despite differing severity of clinical presentation and molecular etiology, the impairment of synaptic function as well as plasticity is seen in both diseases. Here, we will deep dive into recent advances in disease understanding to…Read more

day: Pre-Conference Workshop Day

Workshop B
Rett & Fragile X Syndrome: A Breakdown of Disease Pathophysiology
1.00-4.00
11:29 am

Read more

day: Pre-Conference Workshop Day

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.